Use of Causal Inference Methods in Exploring Gerotherapeutic Benefits of FDA-Approved Medications

Abstract

Randomized controlled trials (RCTs) represent the “gold” standard for validating gerotherapeutics for their potential delaying the onset and progression of varied chronic diseases. However, observational studies designed to guide the design of expensive and lengthy RCTs are subject to nearly unavoidable biases.